MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3390/jcm13237266

Медицинская библиотека · Journal of clinical medicine · 2024

Efficacy and Safety of CT-P13 as First- and Second-Line Treatment in Patients with Ankylosing Spondylitis.

Uslu Sadettin, Gülle Semih, Sen Gercek, Capar Sedat, Senel Soner, Dalkılıc Ediz, Akar Servet, Koca Süleyman Serdar, Tufan Abdurrahman, Yazici Ayten, Yilmaz Sema, Inanc Nevsun, Birlik Merih, Solmaz Dilek, Cefle Ayse, Goker Berna, Direskeneli Haner, Yolbas Servet, Steen Krogh Niels, Yilmaz Neslihan, Erten Sükran, Bes Cemal, Soysal Gündüz Ozgül, Oztürk Mehmet Akif, Haznedaroglu Seminur, Yavuz Sule, Onen Fatos, Sari Ismail

СтатьяПеревод в очереди

Аннотация

Background/

Objectives

CT-P13 is a biosimilar version of infliximab, a monoclonal antibody. In individuals with ankylosing spondylitis (AS), CT-P13 has been shown to be effective and to have a well-tolerated safety profile. The aim of this study was to evaluate the long-term drug persistence, safety, and efficacy of infliximab biosimilar CT-P13 in patients with AS undergoing first-line (1st-line) and later (≥2nd-line) treatment in clinical practice.

Methods

We performed an observational cohort study that included AS patients based on the biological drug database in the TURKBIO Registry between 2014 and 2021. The patients were divided into two groups: those receiving CT-P13 as first-line treatment or as a switch (≥2nd-line) from another TNF inhibitor (TNFi). Standard disease activity metrics were used to assess the effectiveness of CT-P13, and drug retention rates were investigated.

Results

There were 179 AS patients using CT-P13 (47.4% male, mean age: 42.9 ± 11.3 years). Of these patients, 123 (68.7%) were receiving CT-P13 as a first-line treatment. The mean length of treatment was 3.5 years. CT-P13 drug retention rates in the general patient population were 58.6% and 48.2% in the first-line and ≥second-line treatment, respectively, after 3 years of follow-up. The most common reason for CT-P13 treatment discontinuation was lack of efficacy. The first-line CT-P13 group had statistically substantially higher ASAS20/40 response rates at three and six months. Nonetheless, both groups' response rates at one year were comparable.

Conclusions

In this real-world data analysis, AS patients who were TNFi naïve (1st-line) and subsequently treated (≥2nd-line) with CT-P13 showed encouraging drug retention rates with acceptable long-term effectiveness and safety.

Для цитирования: Uslu Sadettin, Gülle Semih, Sen Gercek, Capar Sedat, Senel Soner, Dalkılıc Ediz, Akar Servet, Koca Süleyman Serdar, Tufan Abdurrahman, Yazici Ayten, Yilmaz Sema, Inanc Nevsun, Birlik Merih, Solmaz Dilek, Cefle Ayse, Goker Berna, Direskeneli Haner, Yolbas Servet, Steen Krogh Niels, Yilmaz Neslihan, Erten Sükran, Bes Cemal, Soysal Gündüz Ozgül, Oztürk Mehmet Akif, Haznedaroglu Seminur, Yavuz Sule, Onen Fatos, Sari Ismail. Efficacy and Safety of CT-P13 as First- and Second-Line Treatment in Patients with Ankylosing Spondylitis.. Journal of clinical medicine. 2024. DOI: 10.3390/jcm13237266.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.